1. Liu J, Farmer JD, Jr., Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991 Aug 23;66(4):807-15.
2. Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet. 2004 Apr;5(4):262-75.
3. Chan TF, Carvalho J, Riles L, et al. A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13227-32.
4. Soga S, Neckers LM, Schulte TW, et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 1999 Jun 15;59(12):2931-8.
5. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009 Apr 15;18(R1):R48-59.
6. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-1858.
7. Espay AJ, Morgante F, Merola A, et al. Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol. 2018 Dec;84(6):797-811.
8. Zeng XS, Geng WS, Jia JJ, et al. Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. Front Aging Neurosci. 2018;10:109.
9. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012 Dec;72(6):893-901.
10. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 2009 Aug;35(2):165-76.
11. Athauda D, Foltynie T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol. 2015 Jan;11(1):25-40.
12. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76.
13. Saiki S, Sato S, Hattori N. Molecular pathogenesis of Parkinson's disease: update. J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):430-6.
14. Schipper HM, Liberman A, Stopa EG. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol. 1998 Mar;150(1):60-8.
15. Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci. 2001 May;2(5):325-34.
16. Bae JW, Kim MJ, Jang CG, et al. Protective effects of heme oxygenase-1 against MPP(+)-induced cytotoxicity in PC-12 cells. Neurol Sci. 2010 Jun;31(3):307-13.
17. Falkenburger BH, Saridaki T, Dinter E. Cellular models for Parkinson's disease. J Neurochem. 2016 Oct;139 Suppl 1:121-130.
18. Panahian N, Yoshiura M, Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem. 1999 Mar;72(3):1187-203.
19. Jazwa A, Cuadrado A. Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases. Curr Drug Targets. 2010 Dec;11(12):1517-31.
20. Stocker R, Yamamoto Y, McDonagh AF, et al. Bilirubin is an antioxidant of possible physiological importance. Science. 1987 Feb 27;235(4792):1043-6.
21. Sedlak TW, Saleh M, Higginson DS, et al. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5171-6.
22. Jansen T, Daiber A. Direct Antioxidant Properties of Bilirubin and Biliverdin. Is there a Role for Biliverdin Reductase? Front Pharmacol. 2012;3:30.
23. Yamaguchi T, Komoda Y, Nakajima H. Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem. 1994 Sep 30;269(39):24343-8.
24. Ryter SW, Morse D, Choi AM. Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease. Am J Respir Cell Mol Biol. 2007 Feb;36(2):175-82.
25. Barone E, Di Domenico F, Mancuso C, et al. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol Dis. 2014 Feb;62:144-59.
26. Jeney V, Balla J, Yachie A, et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood. 2002 Aug 1;100(3):879-87.
27. Yanatori I, Tabuchi M, Kawai Y, et al. Heme and non-heme iron transporters in non-polarized and polarized cells. BMC Cell Biol. 2010 Jun 4;11:39.
28. Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000 Apr;6(4):422-8.
29. Almeida AS, Queiroga CS, Sousa MF, et al. Carbon monoxide modulates apoptosis by reinforcing oxidative metabolism in astrocytes: role of Bcl-2. J Biol Chem. 2012 Mar 30;287(14):10761-70.
30. Gowda S, Desai PB, Hull VV, et al. A review on laboratory liver function tests. Pan Afr Med J. 2009 Nov 22;3:17.
31. Inoguchi T, Fukuhara S, Yamato M, et al. Serum bilirubin level is a strong predictor for disability in activities in daily living (ADL) in Japanese elderly patients with diabetes. Sci Rep. 2019 May 8;9(1):7069.
32. Moccia M, Picillo M, Erro R, et al. Increased bilirubin levels in de novo Parkinson's disease. Eur J Neurol. 2015 Jun;22(6):954-9.
33. Qin XL, Zhang QS, Sun L, et al. Lower Serum Bilirubin and Uric Acid Concentrations in Patients with Parkinson's Disease in China. Cell Biochem Biophys. 2015 May;72(1):49-56.
34. Hatano T, Saiki S, Okuzumi A, et al. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):295-301.
35. Lee DY, Oh M, Kim SJ, et al. Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease. Clin Nucl Med. 2019 Nov;44(11):855-859.
36. Macias-Garcia D, Mendez-Del Barrio C, Jesus S, et al. Increased bilirubin levels in Parkinson's disease. Parkinsonism Relat Disord. 2019 Jun;63:213-216.
37. Kumagai A, Ando R, Miyatake H, et al. A bilirubin-inducible fluorescent protein from eel muscle. Cell. 2013 Jun 20;153(7):1602-11.
38. Takeda TA, Mu A, Tai TT, et al. Continuous de novo biosynthesis of haem and its rapid turnover to bilirubin are necessary for cytoprotection against cell damage. Sci Rep. 2015 May 20;5:10488.
39. Iwatani S, Nakamura H, Kurokawa D, et al. Fluorescent protein-based detection of unconjugated bilirubin in newborn serum. Sci Rep. 2016 Jun 21;6:28489.
40. Szymczak-Workman AL, Vignali KM, Vignali DA. Design and construction of 2A peptide-linked multicistronic vectors. Cold Spring Harb Protoc. 2012 Feb 1;2012(2):199-204.
41. Exner N, Lutz AK, Haass C, et al. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012 Jun 26;31(14):3038-62.
42. Foresti R, Motterlini R. The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. Free Radic Res. 1999 Dec;31(6):459-75.
43. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004 Mar;3(3):205-14.
44. Maghzal GJ, Leck MC, Collinson E, et al. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J Biol Chem. 2009 Oct 23;284(43):29251-9.
45. Mancuso C. Bilirubin and brain: A pharmacological approach. Neuropharmacology. 2017 May 15;118:113-123.
46. Dodson M, Redmann M, Rajasekaran NS, et al. KEAP1-NRF2 signalling and autophagy in protection against oxidative and reductive proteotoxicity. Biochem J. 2015 Aug 1;469(3):347-55.
47. Martin D, Rojo AI, Salinas M, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem. 2004 Mar 5;279(10):8919-29.
48. Jain A, Lamark T, Sjottem E, et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem. 2010 Jul 16;285(29):22576-91.
49. Villeneuve NF, Lau A, Zhang DD. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal. 2010 Dec 1;13(11):1699-712.
50. Lo SC, Li X, Henzl MT, et al. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. Embo J. 2006 Aug 9;25(15):3605-17.
51. Chen Y, Inoyama D, Kong AN, et al. Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance. Chem Biol Drug Des. 2011 Dec;78(6):1014-21.
52. Barone MC, Sykiotis GP, Bohmann D. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Dis Model Mech. 2011 Sep;4(5):701-7.
53. He Q, Song N, Jia F, et al. Role of alpha-synuclein aggregation and the nuclear factor E2-related factor 2/heme oxygenase-1 pathway in iron-induced neurotoxicity. Int J Biochem Cell Biol. 2013 Jun;45(6):1019-30.
54. Gan L, Johnson JA. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. Biochim Biophys Acta. 2014 Aug;1842(8):1208-18.
55. Kulasekaran G, Ganapasam S. Neuroprotective efficacy of naringin on 3-nitropropionic acid- induced mitochondrial dysfunction through the modulation of Nrf2 signaling pathway in PC12 cells. Mol Cell Biochem. 2015 Nov;409(1-2):199-211.
56. Tsou YH, Shih CT, Ching CH, et al. Treadmill exercise activates Nrf2 antioxidant system to protect the nigrostriatal dopaminergic neurons from MPP+ toxicity. Exp Neurol. 2015 Jan;263:50- 62.
57. Zhao P, Yang X, Yang L, et al. Neuroprotective effects of fingolimod in mouse models of Parkinson's disease. FASEB J. 2017 Jan;31(1):172-179.
58. Wakabayashi K, Tanji K, Odagiri S, et al. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol. 2013 Apr;47(2):495-508.
59. Yu Q, Zhang H, Li Y, et al. UCH-L1 Inhibition Suppresses tau Aggresome Formation during Proteasomal Impairment. Mol Neurobiol. 2018 May;55(5):3812-3821.
60. Olzmann JA, Li L, Chin LS. Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem. 2008;15(1):47-60.
61. Butterfield DA, Reed T, Newman SF, et al. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med. 2007 Sep 1;43(5):658-77.
62. Bakken AF, Thaler MM, Schmid R. Metabolic regulation of heme catabolism and bilirubin production. I. Hormonal control of hepatic heme oxygenase activity. J Clin Invest. 1972 Mar;51(3):530-6.
63. Sun J, Hoshino H, Takaku K, et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J. 2002 Oct 1;21(19):5216-24.
64. Kitamuro T, Takahashi K, Ogawa K, et al. Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J Biol Chem. 2003 Mar 14;278(11):9125-33.
65. Suzuki H, Tashiro S, Sun J, et al. Cadmium induces nuclear export of Bach1, a transcriptional repressor of heme oxygenase-1 gene. J Biol Chem. 2003 Dec 5;278(49):49246-53.
66. Farombi EO, Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol. 2006 Sep 30;39(5):479-91.
67. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009 May 15;284(20):13291-5.
68. Theodore M, Kawai Y, Yang J, et al. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. J Biol Chem. 2008 Apr 4;283(14):8984-94.
69. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11908-13.
70. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003 Nov;23(22):8137-51.
71. Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012 Jul;32(4):687-726.
72. Jiang ZY, Lu MC, You QD. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions. J Med Chem. 2016 Dec 22;59(24):10837-10858.
73. Cuadrado A, Rojo AI, Wells G, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
74. Castellani R, Smith MA, Richey GL, et al. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Research. 1996;737(1-2):195-200.
75. Schipper HM. Experimental induction of corpora amylacea in adult rat brain. Microscopy Research and Technique. 1998;43(1):43-48.
76. Ramsey CP, Glass CA, Montgomery MB, et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol. 2007 Jan;66(1):75-85.
77. Jakel RJ, Kern JT, Johnson DA, et al. Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro. Toxicol Sci. 2005 Sep;87(1):176-86.
78. Innamorato NG, Jazwa A, Rojo AI, et al. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One. 2010 Jul 28;5(7):e11838.
79. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress. Cell. 2003;115(6):727-738.
80. Taylor JP, Tanaka F, Robitschek J, et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet. 2003 Apr 1;12(7):749-57.
81. Tanaka M, Kim YM, Lee G, et al. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem. 2004 Feb 6;279(6):4625-31.
82. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72.
83. Kataura T, Saiki S, Ishikawa KI, et al. BRUP-1, an intracellular bilirubin modulator, exerts neuroprotective activity in a cellular Parkinson's disease model. J Neurochem. 2020 Mar 3.
84. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
85. Vasavda C, Kothari R, Malla AP, et al. Bilirubin Links Heme Metabolism to Neuroprotection by Scavenging Superoxide. Cell Chem Biol. 2019 Oct 17;26(10):1450-1460.e7.
86. Fujimaki T, Saiki S, Tashiro E, et al. Identification of licopyranocoumarin and glycyrurol from herbal medicines as neuroprotective compounds for Parkinson's disease. PLoS One. 2014;9(6):e100395.
87. Igarashi Y, Matsuoka N, In Y, et al. Nonthmicin, a Polyether Polyketide Bearing a Halogen- Modified Tetronate with Neuroprotective and Antiinvasive Activity from Actinomadura sp. Org Lett. 2017 Mar 17;19(6):1406-1409.
88. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222.
89. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013 Aug;19(8):983- 97.
90. Sarkar S. Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochem Soc Trans. 2013 Oct;41(5):1103-30.
91. Williams A, Sarkar S, Cuddon P, et al. Novel targets for Huntington's disease in an mTOR- independent autophagy pathway. Nat Chem Biol. 2008 May;4(5):295-305.
92. Dunlop EA, Tee AR. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol. 2014 Dec;36:121-9.
93. Martina JA, Chen Y, Gucek M, et al. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012 Jun;8(6):903-14.
94. Zhou J, Liao W, Yang J, et al. FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway. Autophagy. 2012 Dec;8(12):1712-23.
95. Song S, Tan J, Miao Y, et al. Crosstalk of ER stress-mediated autophagy and ER-phagy: Involvement of UPR and the core autophagy machinery. J Cell Physiol. 2018 May;233(5):3867- 3874.
96. Magi S, Tashiro E, Imoto M. A chemical genomic study identifying diversity in cell migration signaling in cancer cells. Sci Rep. 2012;2:823.
97. Kaizuka T, Morishita H, Hama Y, et al. An Autophagic Flux Probe that Releases an Internal Control. Mol Cell. 2016 Nov 17;64(4):835-849.
98. Xi H, Kurtoglu M, Liu H, et al. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol. 2011 Apr;67(4):899- 910.
99. Kornicka K, Szlapka-Kosarzewska J, Smieszek A, et al. 5-Azacytydine and resveratrol reverse senescence and ageing of adipose stem cells via modulation of mitochondrial dynamics and autophagy. J Cell Mol Med. 2019 Jan;23(1):237-259.
100. Selimovic D, Porzig BB, El-Khattouti A, et al. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal. 2013 Jan;25(1):308- 18.
101. Ding WX, Ni HM, Gao W, et al. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem. 2007 Feb 16;282(7):4702-10.
102. Geng X, Ma L, Li Z, et al. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas. World Neurosurg. 2017 Apr;100:407-416.
103. Apolloni S, Fabbrizio P, Amadio S, et al. Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression. J Neuroinflammation. 2016 Aug 22;13(1):191.
104. You L, Shou J, Deng D, et al. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget. 2015 Nov 24;6(37):40268-82.
105. Yoo YM, Jeung EB. Melatonin suppresses cyclosporine A-induced autophagy in rat pituitary GH3 cells. J Pineal Res. 2010 Apr;48(3):204-11.
106. Milano V, Piao Y, LaFortune T, et al. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther. 2009 Feb;8(2):394-406.
107. Wu Y, Li X, Xie W, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205.
108. Zheng ZY, Li J, Li F, et al. Induction of N-Ras degradation by flunarizine-mediated autophagy. Sci Rep. 2018 Nov 16;8(1):16932.
109. Dou Q, Chen HN, Wang K, et al. Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer. Cancer Res. 2016 Aug 1;76(15):4457-69.
110. Sakamaki JI, Wilkinson S, Hahn M, et al. Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function. Mol Cell. 2017 May 18;66(4):517-532.e9.
111. Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005 Sep 26;170(7):1101-11.
112. Hirano K, Fujimaki M, Sasazawa Y, et al. Neuroprotective effects of memantine via enhancement of autophagy. Biochem Biophys Res Commun. 2019 Oct 8;518(1):161-170.
113. Bao W, Gu Y, Ta L, et al. Induction of autophagy by the MG132 proteasome inhibitor is associated with endoplasmic reticulum stress in MCF7 cells. Mol Med Rep. 2016 Jan;13(1):796-804.
114. Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy. FEBS Lett. 2010 Apr 2;584(7):1287-95.
115. Morselli E, Marino G, Bennetzen MV, et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol. 2011 Feb 21;192(4):615-29.
116. Oh M, Choi IK, Kwon HJ. Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun. 2008 May 16;369(4):1179-83.
117. Kiga M, Nakayama A, Shikata Y, et al. SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in beta-catenin-mutated tumors. Sci Rep. 2015 Feb 2;5:8155.
118. Prieto-Dominguez N, Ordonez R, Fernandez A, et al. Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol. 2016;7:151.
119. Ha JY, Kim JS, Kim SE, et al. Simultaneous activation of mitophagy and autophagy by staurosporine protects against dopaminergic neuronal cell death. Neurosci Lett. 2014 Feb 21;561:101-6.
120. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009 Mar 20;284(12):8023-32.
121. Zhang J, Ng S, Wang J, et al. Histone deacetylase inhibitors induce autophagy through FOXO1- dependent pathways. Autophagy. 2015 Apr 3;11(4):629-42.
122. Ogata M, Hino S, Saito A, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol. 2006 Dec;26(24):9220-31.
123. Yang JW, Zhang QH, Liu T. Autophagy facilitates anticancer effect of 5-fluorouracil in HCT-116 cells. J Cancer Res Ther. 2018 Dec;14(Supplement):S1141-s1147.
124. Cortes CL, Veiga SR, Almacellas E, et al. Effect of low doses of actinomycin D on neuroblastoma cell lines. Mol Cancer. 2016 Jan 4;15:1.
125. Cabrera S, Maciel M, Herrera I, et al. Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis. Autophagy. 2015 Apr 3;11(4):670-84.
126. Vanzo R, Bartkova J, Merchut-Maya JM, et al. Autophagy role(s) in response to oncogenes and DNA replication stress. Cell Death Differ. 2019 Aug 14.
127. Kwon KY, Viollet B, Yoo OJ. CCCP induces autophagy in an AMPK-independent manner. Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):343-8.
128. Han W, Sun J, Feng L, et al. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One. 2011;6(12):e28491.
129. Koleini N, Kardami E. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget. 2017 Jul 11;8(28):46663-46680.
130. Maskey D, Yousefi S, Schmid I, et al. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun. 2013;4:2130.
131. Ding WX, Ni HM, Gao W, et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol. 2007 Aug;171(2):513-24.
132. Ojha R, Jha V, Singh SK. Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells. Biochim Biophys Acta. 2016 Feb;1863(2):347-59.
133. Zamora A, Alves M, Chollet C, et al. Paclitaxel induces lymphatic endothelial cells autophagy to promote metastasis. Cell Death Dis. 2019 Dec 20;10(12):956.
134. Dupont N, Jiang S, Pilli M, et al. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta. Embo J. 2011 Nov 8;30(23):4701-11.
135. Wu Q, Wang X, Nepovimova E, et al. Mechanism of cyclosporine A nephrotoxicity: Oxidative stress, autophagy, and signalings. Food Chem Toxicol. 2018 Aug;118:889-907.
136. Atkins C, Liu Q, Minthorn E, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013 Mar 15;73(6):1993-2002.
137. Bertolotti A, Zhang Y, Hendershot LM, et al. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol. 2000 Jun;2(6):326-32.
138. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic- reticulum-resident kinase. Nature. 1999 Jan 21;397(6716):271-4.
139. Pakos-Zebrucka K, Koryga I, Mnich K, et al. The integrated stress response. EMBO Rep. 2016 Oct;17(10):1374-1395.
140. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007 Sep-Oct;3(5):452-60.
141. Kiga M, Tanzawa F, Iwasaki S, et al. Antitumor effects of novel highly hydrophilic and non-ATP- competitive MEK1/2 inhibitor, SMK-17. Anticancer Drugs. 2012 Jan;23(1):119-30.
142. Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011 Jun 17;332(6036):1429-33.
143. Settembre C, Zoncu R, Medina DL, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. Embo J. 2012 Mar 7;31(5):1095-108.
144. Rusmini P, Cortese K, Crippa V, et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy. 2019 Apr;15(4):631-651.
145. Li Y, Xu M, Ding X, et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. Nat Cell Biol. 2016 Oct;18(10):1065-77.
146. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006 Oct 19;443(7113):787-95.
147. Shinjo S, Mizotani Y, Tashiro E, et al. Comparative analysis of the expression patterns of UPR- target genes caused by UPR-inducing compounds. Biosci Biotechnol Biochem. 2013;77(4):729- 35.
148. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41.
149. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998 May;50(5):1323-6.
150. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006 Feb;6(1):61-7.
151. Hayashi T. The Sigma-1 Receptor in Cellular Stress Signaling. Front Neurosci. 2019;13:733.
152. Kubickova J, Lencesova L, Csaderova L, et al. Haloperidol Affects Plasticity of Differentiated NG-108 Cells Through sigma1R/IP3R1 Complex. Cell Mol Neurobiol. 2018 Jan;38(1):181-194.
153. Nishitoh H, Matsuzawa A, Tobiume K, et al. ASK1 is essential for endoplasmic reticulum stress- induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 2002 Jun 1;16(11):1345-55.
154. Margariti A, Li H, Chen T, et al. XBP1 mRNA splicing triggers an autophagic response in endothelial cells through BECLIN-1 transcriptional activation. J Biol Chem. 2013 Jan 11;288(2):859-72.
155. Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017 Dec 2;390(10111):2481-2489.
156. Apolloni S, Fabbrizio P, Parisi C, et al. Clemastine Confers Neuroprotection and Induces an Anti- Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2016 Jan;53(1):518-531.
157. Nicolau-Galmes F, Asumendi A, Alonso-Tejerina E, et al. Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms. Apoptosis. 2011 Dec;16(12):1253-67.
158. Hu WW, Yang Y, Wang Z, et al. H1-antihistamines induce vacuolation in astrocytes through macroautophagy. Toxicol Appl Pharmacol. 2012 Apr 15;260(2):115-23.
159. Jakhar R, Paul S, Bhardwaj M, et al. Astemizole-Histamine induces Beclin-1-independent autophagy by targeting p53-dependent crosstalk between autophagy and apoptosis. Cancer Lett. 2016 Mar 1;372(1):89-100.
160. Jangi SM, Ruiz-Larrea MB, Nicolau-Galmes F, et al. Terfenadine-induced apoptosis in human melanoma cells is mediated through Ca2+ homeostasis modulation and tyrosine kinase activity, independently of H1 histamine receptors. Carcinogenesis. 2008 Mar;29(3):500-9.
161. B'Chir W, Maurin AC, Carraro V, et al. The eIF2alpha/ATF4 pathway is essential for stress- induced autophagy gene expression. Nucleic Acids Res. 2013 Sep;41(16):7683-99.
162. Py BF, Boyce M, Yuan J. A critical role of eEF-2K in mediating autophagy in response to multiple cellular stresses. Autophagy. 2009 Apr;5(3):393-6.
163. Dever TE. Gene-specific regulation by general translation factors. Cell. 2002 Feb 22;108(4):545- 56.
164. Kinsey CG, Camolotto SA, Boespflug AM, et al. Protective autophagy elicited by RAF-->MEK-->ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019 Apr;25(4):620-627.
165. Chauhan S, Goodwin JG, Chauhan S, et al. ZKSCAN3 is a master transcriptional repressor of autophagy. Mol Cell. 2013 Apr 11;50(1):16-28.
166. Le Good JA, Ziegler WH, Parekh DB, et al. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science. 1998 Sep 25;281(5385):2042-5.
167. Squier TC. Oxidative stress and protein aggregation during biological aging. Exp Gerontol. 2001 Sep;36(9):1539-50.
168. Kao C, Chao A, Tsai CL, et al. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Cell Death Dis. 2014 Nov 6;5:e1510.
169. Ji MM, Lee JM, Mon H, et al. Proteasome inhibitor MG132 impairs autophagic flux through compromising formation of autophagosomes in Bombyx cells. Biochem Biophys Res Commun. 2016 Oct 28;479(4):690-696.
170. Wang D, Xu Q, Yuan Q, et al. Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab. Oncogene. 2019 May;38(18):3458-3474.
171. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002 Apr;82(2):373-428.
172. Marambio P, Toro B, Sanhueza C, et al. Glucose deprivation causes oxidative stress and stimulates aggresome formation and autophagy in cultured cardiac myocytes. Biochim Biophys Acta. 2010 Jun;1802(6):509-18.
173. Katoh-Semba R, Kitajima S, Yamazaki Y, et al. Neuritic growth from a new subline of PC12 pheochromocytoma cells: cyclic AMP mimics the action of nerve growth factor. J Neurosci Res. 1987;17(1):36-44.
174. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11400-6.
175. Suzuki A, Obi K, Urabe T, et al. Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein. J Neurochem. 2002 Aug;82(4):953-60.
176. Shikata Y, Yoshimaru T, Komatsu M, et al. Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor. Cancer Sci. 2017 Apr;108(4):785- 794.
177. Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nat Rev Neurol. 2016 Oct 27;12(11):622-634.
論文の公開元へ
